PAREXEL and Osaka International Cancer Institute have formed an alliance to advance clinical development in Japan. The partnership aims to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, to help accelerate the development of new cancer treatments.

“Oncology continues to be the largest therapeutic area in clinical trials today, and is a priority for PAREXEL as we partner with clients to deliver new therapies to patients in need,” said Shogo Nakamori, corporate vice president, Clinical Research Services, Asia Pacific, PAREXEL. “Osaka International Cancer Institute is a center of excellence for clinical trials in the Kansai region of Japan. Through this alliance, PAREXEL and the Osaka International Cancer Institute will work to drive greater efficiencies for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this difficult disease area.”

“The advancement of clinical trials in oncology is imperative in the development of promising new therapies for patients in Japan and around the world,” said Dr. Nariaki Matsuura, president of Osaka International Cancer Institute. “We are pleased to be working with PAREXEL, an innovative partner with a large presence in Japan, and globally, with leading clinical and scientific expertise in oncology. Through this collaboration, Osaka International Cancer Institute will gain access to novel treatments sooner, providing a wider range of potential treatment options for our patients and allowing us to make a strong contribution to the further advancement of cancer treatments.”

PAREXEL established operations in Japan in 1995 and has more than 1,300 employees based in Tokyo, Kobe, and Osaka.